United Therapeutics
✦ Quant Ownership Signal how this is computed
- The number of reporting institutions decreased by 4 in the most recent period (2026/Q4).
- Total institutional ownership fell 0.6 percentage points.
Ownership vs. money flow
DivergingInstitutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 104.35% -0.59pp
- Institutions
- 1,044 -4
- As of
- 2026/Q4 vs. prior period
Holder types
Top holders as of 2026-09-30
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 0 buys · 50 sells
| Name | Role | Stake |
|---|---|---|
| Martine Rothblatt | Chairperson & CEO | 1.57% |
| Paul Mahon | General Counsel | 0.11% |
| Thomas Thompson | Independent Director | 0.05% |
| Richard Giltner | Independent Director | 0.05% |
| Michael Benkowitz | President | 0.05% |
| James Edgemond | Chief Financial Officer | 0.04% |
| Raymond Kurzweil | Independent Director | 0.03% |
| Nilda Mesa | Independent Director | 0.01% |
| Judy Olian | Independent Director | 0.01% |
| Louis Sullivan | Independent Director & Member of the Scientific Advisory Board | 0.01% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-11-11 | Martine Rothblatt | Chairperson & CEO | Derivative Exercise and Sale | -9,500 | $117.76–597.33 |
| 2026-11-08 | Christopher Patusky | Independent Vice Chairman & Lead Independent Director | Derivative Exercise and Sale | -1,210 | $132.30–580.00 |
| 2026-11-05 | Martine Rothblatt | Chairperson & CEO | Derivative Exercise and Sale | -9,500 | $117.76–568.68 |
| 2026-11-04 | Paul Mahon | General Counsel | Derivative Exercise and Sale | -8,300 | $146.03–602.72 |
| 2026-11-02 | Martine Rothblatt | Chairperson & CEO | Derivative Exercise and Sale | -9,500 | $117.76–605.97 |
| 2026-11-01 | Martine Rothblatt | Chairperson & CEO | Derivative Exercise and Sale | -9,500 | $117.76–598.84 |
| 2026-10-29 | Martine Rothblatt | Chairperson & CEO | Derivative Exercise and Sale | -9,500 | $117.76–608.05 |
| 2026-10-28 | Martine Rothblatt | Chairperson & CEO | Derivative Exercise and Sale | -9,500 | $117.76–599.30 |
| 2026-10-27 | Martine Rothblatt | Chairperson & CEO | Derivative Exercise and Sale | -9,500 | $117.76–588.39 |
| 2026-10-26 | Martine Rothblatt | Chairperson & CEO | Derivative Exercise and Sale | -9,500 | $117.76–592.84 |
| 2026-10-25 | Martine Rothblatt | Chairperson & CEO | Derivative Exercise and Sale | -9,500 | $117.76–592.92 |
| 2026-10-22 | Martine Rothblatt | Chairperson & CEO | Derivative Exercise and Sale | -9,500 | $117.76–588.00 |
| 2026-10-21 | Martine Rothblatt | Chairperson & CEO | Derivative Exercise and Sale | -9,500 | $117.76–590.40 |
| 2026-10-20 | Martine Rothblatt | Chairperson & CEO | Derivative Exercise and Sale | -9,500 | $117.76–566.43 |
| 2026-10-19 | Martine Rothblatt | Chairperson & CEO | Derivative Exercise and Sale | -9,500 | $117.76–563.56 |
| 2026-10-18 | Martine Rothblatt | Chairperson & CEO | Derivative Exercise and Sale | -9,500 | $117.76–556.88 |
| 2026-10-15 | Martine Rothblatt | Chairperson & CEO | Derivative Exercise and Sale | -9,500 | $117.76–543.85 |
| 2026-10-14 | Martine Rothblatt | Chairperson & CEO | Derivative Exercise and Sale | -9,500 | $117.76–551.50 |
| 2026-10-14 | Paul Mahon | General Counsel | Intent to Sell (Form 144) | -8,300 | $544.30 |
| 2026-10-14 | Paul Mahon | General Counsel | Derivative Exercise and Sale | -8,300 | $146.03–546.56 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 20:02:22 · For reference only, not investment advice and not tailored to your situation.
United Therapeutics discussion 0 comments